

PHARMACY POLICY STATEMENT

Indiana Medicaid

DRUG NAME	Adzynma (ADAMTS13, recombinant-krhn)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Adzynma, approved by the FDA in 2023, is a recombinant human ADAMTS13 protein consisting of disintegrin and metalloproteinase with thrombospondin type 1 motifs (ADAMTS13). It is used as a replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). Adzynma is the first treatment approved for cTTP. Hereditary TTP is much less common than acquired/immune TTP.

Endogenous ADAMTS13 regulates the activity of von Willebrand factor (VWF) by cleaving it into smaller units to reduce its platelet binding properties and microthrombi formation. TTP results from a deficiency of ADAMTS13 which leads to increased circulation of VWF causing clotting and red blood cell destruction. Signs and symptoms can include thrombocytopenia, hemolytic anemia, neurological symptoms, and a skin rash. Plasma infusions have been the main treatment for cTTP, to provide sufficient ADAMTS13.

Adzynma (ADAMTS13, recombinant-krhn) will be considered for coverage when the following criteria are met:

Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

For **initial** authorization:

1. Medication must be prescribed by or in consultation with a hematologist; AND
2. Member has a diagnosis of cTTP confirmed by BOTH of the following:
 - a) Genetic test results demonstrating *ADAMTS13* gene mutation and
 - b) Plasma ADAMTS13 activity level <10% of normal (<10 IU/dL).
3. **Dosage allowed/Quantity limit:**
 Prophylaxis: 40 IU/kg IV once every other week; may adjust to once weekly.
 On-Demand: 40 IU/kg on day 1, 20 IU/kg on day 2, 15 IU/kg on day 3 and beyond until two days after the acute event is resolved.

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes must show improvement or stabilized signs and symptoms of disease such as fewer acute TTP events, increased ADAMTS13 activity, or increased platelet count with treatment.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Adzynma (ADAMTS13, recombinant-krhn) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

